Page 49 - AN-1-1

Advanced Neurology Insights on ARIA

34. Ostrowitzki S, Lasser RA, Dorflinger E, et al., 2017, A nondemented brains correlates with APOE e4. Neurosci
phase III randomized trial of gantenerumab in prodromal Lett., 473(3): 168–171.
Alzheimer’s disease. Alzheimers Res Ther, 9(1): 95.
http://doi.org/10.1016/j.neulet.2010.02.016
http://doi.org/10.1186/s13195-017-0318-y
44. Harrison CH, Sakai K, Johnston DA et al., 2019, The Role
35. Swanson CJ, Zhang Y, Dhadda S, et al., 2021, A randomized, of Capillary Angiopathy and Aquaporin 4 in Aria Induced
double-blind, phase 2b proof-of-concept clinical trial in by Aβ Immunization, Oral Presentation at AAIC 2019 (O3-
early Alzheimer’s disease with lecanemab, an anti-Abeta 10-03).
protofibril antibody. Alzheimers Res Ther, 13(1): 80. 45. Blockx I, Einstein S, Guns PJ, et al., 2016, Monitoring
http://doi.org/10.1186/s13195-021-00813-8 blood-brain barrier integrity following amyloid-beta
immunotherapy using gadolinium-enhanced MRI in a
36. Arrighi HM, Barakos J, Barkhof F, et al., 2016, PDAPP mouse model. J Alzheimers Dis, 54(2): 723–735.
Amyloid- related imaging abnormalities-haemosiderin
(ARIA-H) in patients with Alzheimer’s disease treated with http://doi.org/10.3233/JAD-160023
bapineuzumab: A historical, prospective secondary analysis. 46. Eng JA, Frosch MP, Choi K, et al., 2004, Clinical
J Neurol Neurosurg Psychiatry, 87(1): 106–112. manifestations of cerebral amyloid angiopathy-related
http://doi.org/10.1136/jnnp-2014-309493 inflammation. Ann Neurol, 55(2): 250–256.
37. Chalkias S, Umans K, Castrillo-Viguera C, et al., 2021, http://doi.org/10.1002/ana.10810
Considerations for the Real-World Management of ARIA 47. Kinnecom C, Lev MH, Wendell L, et al., 2007, Course
From the Aducanumab Phase 3 Studies EMERGE and of cerebral amyloid angiopathy-related inflammation.
ENGAGE. AAIC 2021 Poster 57498. Neurology, 68(17): 1411–1416.
38. Liu E, Wang D, Sperling R, et al., 2018, Biomarker Pattern of http://doi.org/10.1212/01.wnl.0000260066.98681.2e
ARIA-E Participants in Phase 3 Randomized Clinical Trials
with Bapineuzumab. Neurology, 90(10): e877–e886. 48. Piazza F, Greenberg SM, Savoiardo M, et al., 2013,
Anti- amyloid beta autoantibodies in cerebral amyloid
39. Budd HS, O’Gorman J, Chiao P, et al., 2017, Clinical angiopathy- related inflammation: Implications for amyloid-
development of aducanumab, an anti-abeta human modifying therapies. Ann Neurol, 73(4): 449–458.
monoclonal antibody being investigated for the treatment
of early Alzheimer’s disease. J Prev Alzheimers Dis, 4(4): http://doi.org/10.1002/ana.23857
255–263. 49. Administration, US, FDA. Drugs@FDA: FDA Approved
http://doi.org/10.14283/jpad.2017.39 Drugs. Aducanumab; 2021. Available from: https://www.
fda.gov/drugs/news-events-human-drugs/fdas-decision-
40. Salloway S, Sperling R, Fox NC, et al., 2014, Two phase 3 approve-new-treatment-alzheimers-disease [Last accessed
trials of bapineuzumab in mild-to-moderate Alzheimer’s on 2022 Mar 16].
disease. N Engl J Med, 370(4): 322–333.
50. Mullard A, 2021, Landmark Alzheimer’s drug approval
http://doi.org/10.1056/NEJMoa1304839 confounds research community. Nature, 594(7863):
41. Zago W, Schroeter S, Guido T, et al., 2013, Vascular 309–310.
alterations in PDAPP mice after anti-Abeta immunotherapy: http://doi.org/10.1038/d41586-021-01546-2
Implications for amyloid-related imaging abnormalities.
Alzheimers Dement, 9 Suppl 5: S105–S115. 51. Steinbrook R, 2021, The accelerated approval of aducanumab
for treatment of patients with Alzheimer disease. JAMA
http://doi.org/10.1016/j.jalz.2012.11.010 Intern Med, 181(10): 1281.
42. Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, http://doi.org/10.1001/jamainternmed.2021.4622
et al., 2020, Cerebral amyloid angiopathy and Alzheimer 52. Planche V, Villain N, 2021, US food and drug administration
disease- one peptide, two pathways. Nat Rev Neurol, 16(1): approval of aducanumab-is amyloid load a valid surrogate
30–42.
end point for Alzheimer disease clinical trials? JAMA
http://doi.org/10.1038/s41582-019-0281-2 Neurol, 78(11): 1307–1308.
43. Caselli RJ, Walker D, Sue L, et al., 2010, Amyloid load in http://doi.org/10.1001/jamaneurol.2021.3126

Volume 1 Issue 1 (2022) 9 https://doi.org/10.36922/an.v1i1.2